Fibrosis Pipeline Review H2 2015

1. Fibrosis - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 28-Oct-2015 No. of Pages:97 Single User License: US $2000 Browse more Reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Fibrosis - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Fibrosis - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Abeome Corporation, Acceleron Pharma, Inc., Complexa, Inc., Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., FibroGen, Inc., GlycoMimetics, Inc., HanAll Biopharma Co., Ltd., Isarna Therapeutics GmbH, Lycera Corp., miRagen Therapeutics, Inc., Neumedicines Inc., Ribomic Inc., RuiYi Inc., Scholar Rock, Inc., Siena Biotech S.p.A., Silence Therapeutics Plc, SK Chemicals Co., Ltd., UCB S.A. and XOMA Corporation ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Fibrosis - Pipeline Review, H2 2015 Drugs Profile Discussed in this Research: ACE-2531, Antibodies for Fibrosis, Antibody to Inhibit Transglutaminase 2 for Fibrosis, disitertide, Drug to Activate Insulin Like Growth Factor for Fibrosis, G-XXX, HL-156FIB, IB-DMD, ISTH-1047, MGN-4220, Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis, Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis, NCE-401, NMIL-121, NPH-09, P-006, PRI-724, RBM-003, RBM-007, RG-6069, RNAi Oligonucleotide for Liver Diseases, RYI-028, Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease, Small Molecule to Inhibit LOXL2 for Fibrosis, Small Molecule to Inhibit MicroRNA for Vascular Fibrosis, Small Molecule to Inhibit Rho Kinase for Fibrosis, Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology, Small Molecules for Inflammatory Diseases and Fibrosis, Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis, Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis, Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis, Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD, Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases, Trophokine and XOMA-089 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Fibrosis - Pipeline Review, H2 2015 Scope For Fibrosis - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Fibrosis • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Fibrosis - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Fibrosis • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

7. Fibrosis - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441